ClinicalTrials.gg
CompletedNCT03040713Updated Sep 25, 2020Results posted

Flortaucipir PET Imaging in Subjects With FTD

A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Frontotemporal Dementia, sponsored by Avid Radiopharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-25.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.

Enrollment
56th of 66
16 · median 60
Started
2017
with 7 others
Phase 1
8 of 103
1 open now
Registered
35th of 103
by date

Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2017, is one of 8 in phase 1, and was the 35th registered.

Frontotemporal Dementia

208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.

Browse Frontotemporal Dementia studies →

Open to participants now

31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Frontotemporal Dementia with a site in United States, or all of them as a file.
02

Study summary

This study is designed to assess the usefulness of flortaucipir in Positron Emission Tomography (PET) imaging for subjects diagnosed with Frontotemporal Dementia (FTD).

03

Conditions studied

  • Frontotemporal Dementia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects diagnosed by a dementia specialist with symptomatic clinical syndromes with expected Frontotemporal Dementia (FTD) pathology will be enrolled. Clinical syndromes associated with FTD pathology include: behavioral-variant FTD, FTD with motor-neuron disease, non-fluent/agrammatic and semantic variants of primary progressive aphasia, progressive supranuclear palsy syndrome and corticobasal syndrome.
  • Have provided or have a legally authorized (LAR) provide consent for study procedures
  • Have had volumetric brain MRI obtained in site's companion protocol within one year of enrollment
  • Can tolerate PET scan procedures

Exclusion criteria

Exclusion Criteria:

  • Have cardiac, hepatic, renal, pulmonary, metabolic, or endocrine disturbances that pose potential safety risk
  • Have history of risk factors for Torsades de Pointes (TdP) or taking medication known to cause
  • Have history of drug or alcohol dependence within the last year
  • Are females of who are not surgically sterile, not refraining from sexual activity, or not using reliable
  • Have history of relevant severe drug allergy or
  • Have received an medication under FDA IND protocol within 30 days of planned imaging session
  • Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging session
  • Possess PET scan evidence of amyloid deposition
  • Determined by the investigator to be unsuitable for this type of study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    FTD Subjects

    Subjects diagnosed by dementia specialist with a clinical Frontotemporal Dementia (FTD) syndrome and expected tau or tar DNA binding protein (TDP)-43 pathology receiving a flortaucipir PET scan

    Drug: Flortaucipir F18 · Procedure: Brain PET scan

Interventions

  • 370 megabecquerel (MBq)(10 millicurie \[mCi\]) injection, single dose

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748, Tauvid

  • ProcedureBrain PET scan

    positron emission tomography (PET) scan of the brain

06

What researchers measure

Primary outcomes

  1. Qualitative Evaluation of Flortaucipir PET Scans

    Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's Disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.

    Time frame: baseline scan

  2. Quantitative Evaluation of Flortaucipir PET Scans

    Standard Uptake Value Ratio (SUVr) using a weighted cortical average (MUBADA), and individual regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

    Time frame: baseline scan

07

Results

Posted Sep 25, 2020

Participant flow

Enrollment occurred between Apr 2017 and Oct 2018.

Participant flow — Overall Study
MilestoneFTD Subjects
Started16
Completed13
Not completed3
Withdrew: Positive amyloid scan3

Outcome measures

PrimaryQualitative Evaluation of Flortaucipir PET Scans

Subject scans were visually evaluated by an expert reader into three groups. Advanced Alzheimer's Disease (AD) scan pattern = In either hemisphere, increased neocortical activity in the parietal/precuneus region(s), or frontal region(s) with increased uptake in the posterolateral temporal (PLT), parietal, or occipital region(s). Moderate AD scan pattern = In either hemisphere, increased neocortical activity limited to the PLT or occipital region(s). Not AD scan pattern = No increased neocortical activity, or increased neocortical activity isolated to the mesial temporal, anterolateral temporal, and/or frontal regions.

Time frame:
baseline scan
Reported as:
Count of participants · Participants
Qualitative Evaluation of Flortaucipir PET Scans
ParticipantsFTD Subjects
Advanced AD Scan Pattern (τAD++)0
Moderate AD Scan Pattern (τAD+)0
Not AD Scan Pattern (τAD-)13
PrimaryQuantitative Evaluation of Flortaucipir PET Scans

Standard Uptake Value Ratio (SUVr) using a weighted cortical average (MUBADA), and individual regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.

Time frame:
baseline scan
Reported as:
Mean · standardized uptake value ratio (SUVr)
Quantitative Evaluation of Flortaucipir PET Scans
standardized uptake value ratio (SUVr)FTD Subjects
MUBADA1.00903 ± 0.036582
Parietal0.91992 ± 0.054753
Temporal0.94920 ± 0.041189
Frontal0.89825 ± 0.086118
Caudate0.63508 ± 0.130466

Adverse events

Collected over AEs were collected at scan visit and for 48 hours after flortaucipir administration.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FTD Subjects Safety Population0/15 (0%)0/15 (0%)4/15 (26.7%)
Most frequent other events
Most frequent other events
EventFTD Subjects Safety Population
Feeling coldGeneral disorders1/15
Injection site painGeneral disorders1/15
HeadacheNervous system disorders1/15
EpistaxisRespiratory, thoracic and mediastinal disorders1/15

Baseline characteristics

All subjects receiving one dose of flortaucipir in the study

Age, Continuous
Age, Continuous(years)FTD Subjects
Mean64.7 ± 6.22
Sex: Female, Male
Sex: Female, Male(Participants)FTD Subjects
Female5
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FTD Subjects
Hispanic or Latino1
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FTD Subjects
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White14
More than one race1
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)FTD Subjects
United States15
MMSE
MMSE(units on a scale)FTD Subjects
Mean25.6 ± 6.38
08

Study locations

3 sites
  • Movement Disorder Center, UCSD
    La Jolla, California 92037, United States
  • Memory and Aging Center, UCSF
    San Francisco, California 94158, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
09

References and documents

Publications

  • Soleimani-Meigooni DN, Iaccarino L, La Joie R, Baker S, Bourakova V, Boxer AL, Edwards L, Eser R, Gorno-Tempini ML, Jagust WJ, Janabi M, Kramer JH, Lesman-Segev OH, Mellinger T, Miller BL, Pham J, Rosen HJ, Spina S, Seeley WW, Strom A, Grinberg LT, Rabinovici GD. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. Brain. 2020 Dec 5;143(11):3477-3494. doi: 10.1093/brain/awaa276. PubMed 33141172 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Oct 2018, 18 months.

Results were first posted in Sep 2020, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 2, 2017
StartActual
Apr 11, 2017
Primary completionActual
Oct 24, 2018
CompletionActual
Oct 24, 2018
Results first posted
Sep 25, 2020
Last update
Sep 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03040713
Responsible party
Sponsor
First posted
Feb 2, 2017
Start date
Apr 11, 2017
Primary completion
Oct 24, 2018
Completion
Oct 24, 2018
Results posted
Sep 25, 2020
Last update
Sep 25, 2020

Study contacts

Chief Medical Officer
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion